Leading the way in Hep C treatment
HARVONI is a prescription medicine used to treat adults with chronic hepatitis C (Hep C) genotype 1, 4, 5, or 6 infection with or without cirrhosis (compensated).
HARVONI transformed Hep C treatment as the first cure with a simple regimen that’s one pill, once a day for the majority of patients. There’s no interferon, no complex regimens.
Now, HARVONI has been prescribed to over a quarter of a million people to cure their Hep C.*
In clinical studies, HARVONI was proven to cure 96–99% of adult patients who had Hep C genotype 1 and no prior treatment with 12 weeks of therapy.† Certain patients were cured with just 8 weeks of therapy.‡ Your Hep C Specialist will determine your length of treatment.
If you don’t have Hep C genotype 1, 4, 5, or 6, learn about another treatment option that may be right for you.
Cure means the Hep C virus is not detected in the blood when measured three months after treatment is completed.
*This information is derived from IMS NPA, IMS NSP™, and IntegriChain® data; data reflect estimated patient starts for HARVONI from 10/2014–9/2016.
†In a study of 865 patients with genotype 1 Hep C and no prior Hep C treatment, with or without cirrhosis (compensated), 99% (210 out of 213) of those who received HARVONI once daily for 12 weeks were cured. In a separate study of 647 patients with GT 1 Hep C, with no prior Hep C treatment and without cirrhosis, 96% (208 out of 216) of those who received HARVONI once daily for 12 weeks were cured.
‡In a study of 647 patients with genotype 1 Hep C, with no prior Hep C treatment and without cirrhosis, 97% (119 out of 123) of those with lower levels of the virus (less than 6 million IU/mL) who received HARVONI once daily for 8 weeks were cured.
These studies did not include patients with advanced cirrhosis (decompensated) or those who have had a liver transplant. Advanced cirrhosis (decompensated) is when the liver is extensively scarred and can no longer do its job effectively.
Have you been treated for Hep C before? See clinical study data for Hep C genotype 1 patients with prior Hep C treatment.
See HARVONI clinical study results
HARVONI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype (GT) 1, 4, 5 or 6 infection with or without cirrhosis (compensated). In those with GT 1 and advanced cirrhosis (decompensated) or with GT 1 or 4 with or without cirrhosis (compensated) who have had a liver transplant, HARVONI is used with ribavirin.
Important Safety Information
What is the most important information I should know about HARVONI?
HARVONI can cause serious side effects, including:
- Hepatitis B virus reactivation: Before starting HARVONI treatment, your healthcare provider will do blood tests to check for hepatitis B infection. If you have ever had hepatitis B, the hepatitis B virus could become active again during and after treatment with HARVONI. This may cause serious liver problems, including liver failure and death. If you are at risk, your healthcare provider will monitor you during and after taking HARVONI.